Dashboard
Manage Tickers

PLUR Pluri Inc.

Nasdaq pluri-biotech.com


$ 4.50 $ -0.10 (-2.3 %)    

Friday, 17-Oct-2025 16:46:39 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 604.92 $ 3.94 (0.66 %)
DIA $ 461.73 $ 2.22 (0.48 %)
SPY $ 665.28 $ 3.75 (0.57 %)
TLT $ 91.09 $ -0.14 (-0.15 %)
GLD $ 391.28 $ -7.46 (-1.88 %)
$ 4.25
$ 4.22
$ 4.21 x 1
$ 4.51 x 43
$ 4.25 - $ 4.35
$ 3.33 - $ 7.13
2,215
na
nm
$ 1.10
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 09-17-2025 06-30-2025 10-K
2 05-13-2025 03-31-2025 10-Q
3 02-11-2025 12-31-2024 10-Q
4 11-12-2024 09-30-2024 10-Q
5 09-18-2024 06-30-2024 10-K
6 05-09-2024 03-31-2024 10-Q
7 02-12-2024 12-31-2023 10-Q
8 11-13-2023 09-30-2023 10-Q
9 09-12-2023 06-30-2023 10-K
10 05-09-2023 03-31-2023 10-Q
11 02-13-2023 12-31-2022 10-Q
12 11-10-2022 09-30-2022 10-Q
13 09-21-2022 06-30-2022 10-K
14 05-09-2022 03-31-2022 10-Q
15 02-07-2022 12-31-2021 10-Q
16 11-08-2021 09-30-2021 10-Q
17 09-13-2021 06-30-2021 10-K
18 05-06-2021 03-31-2021 10-Q
19 02-08-2021 12-31-2020 10-Q
20 11-05-2020 09-30-2020 10-Q
21 09-10-2020 06-30-2020 10-K
22 05-11-2020 03-31-2020 10-Q
23 02-06-2020 12-31-2019 10-Q
24 11-07-2019 09-30-2019 10-Q
25 09-12-2019 06-30-2019 10-K
26 05-06-2019 03-31-2019 10-Q
27 02-06-2019 12-31-2018 10-Q
28 11-07-2018 09-30-2018 10-Q
29 09-12-2018 06-30-2018 10-K
30 05-09-2018 03-31-2018 10-Q
31 02-06-2018 12-31-2017 10-Q
32 11-07-2017 09-30-2017 10-Q
33 09-07-2017 06-30-2017 10-K
34 05-08-2017 03-31-2017 10-Q
35 02-08-2017 12-31-2016 10-Q
36 11-07-2016 09-30-2016 10-Q
37 09-07-2016 06-30-2016 10-K
38 05-09-2016 03-31-2016 10-Q
39 02-08-2016 12-31-2015 10-Q
40 11-05-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

pluris-subsidiary-coffeesai-partners-with-chiapas-coffee-institute-to-launch-cell-based-coffee-manufacturing-in-mexico
Pluri's Subsidiary Coffeesai Partners With...
10/08/2025 13:12:40

Pluri Inc. ("Pluri", the "Company", "we" or "us") (Nasdaq, TASE: PLUR), a leading biotechnology...

Core News & Articles
12 Health Care Stocks Moving In Monday's I...
10/06/2025 17:07:04

pluri-q4-eps-100-misses-073-estimate-sales-398000k-miss-400000k-estimate
Pluri Q4 EPS $(1.00) Misses $(0.73) Estima...
09/17/2025 21:34:21

Pluri (NASDAQ:PLUR) reported quarterly losses of $(1.00) per share which missed the analyst consensus estimate of $(0.73) by 36...

pluri-inc-notified-of-nasdaq-non-compliance-over-audit-committee-independence
Pluri Inc Notified Of Nasdaq Non-Complianc...
09/12/2025 12:03:01

-SEC Filing

Core News & Articles
12 Health Care Stocks Moving In Tuesday's ...
07/01/2025 21:05:47

alliance-global-partners-initiates-coverage-on-pluri-with-buy-rating-announces-price-target-of-12
Alliance Global Partners Initiates Coverag...
06/02/2025 14:15:44

Alliance Global Partners analyst Matthew Venezia initiates coverage on Pluri (NASDAQ:PLUR) with a Buy rating and announces P...

pluri-q3-eps-094-up-from-101-yoy-sales-42700k-up-from-7100k-yoy
Pluri Q3 EPS $(0.94) Up From $(1.01) YoY, ...
05/14/2025 05:35:06

Pluri (NASDAQ:PLUR) reported quarterly losses of $(0.94) per share. This is a 6.93 percent increase over losses of $(1.01) per ...

Core News & Articles
12 Health Care Stocks Moving In Wednesday'...
04/23/2025 17:05:58

pluri-announces-that-us-patent-and-trademark-office-has-issued-patent-covering-the-companys-immune-cell-expansion-technologies
Pluri Announces That U.S. Patent And Trade...
04/10/2025 12:37:26

Latest granted patents reinforce Pluri's position as a leader in Mucosal-Associated Invariant T ("MAIT") cell-based...

pluri-signs-exclusive-collaboration-with-hemafund-to-establish-initiative-for-stockpiling-distribution-and-potential-clinical-advancement-of-pluris-plx-r18-cell-therapy-for-hematopoietic-acute-radiation-syndrome-says-collaboration-may-potentially-generate-over-100-million-in-value-for-both-parties
Pluri Signs Exclusive Collaboration With H...
03/05/2025 12:08:28

pluri-signed-an-exclusive-collaboration-agreement-with-hemafund-a-ukrainian-umbilical-cord-blood-bank-with-clinical-and-research-laboratories-and-facilities-specializing-in-cell-preservation-and-cryostorage
Pluri Signed An Exclusive Collaboration Ag...
03/05/2025 12:07:39

This Collaboration aims to establish a strategic initiative for stockpiling, distribution, and potential clinical advancement o...

pluri-announces-additional-35m-investment-from-merchant-adventure-fund-lp
Pluri Announces Additional $3.5M Investmen...
02/04/2025 12:12:25

pluri-shares-are-trading-higher-after-the-company-announced-a-private-placement-and-the-acquisition-of-a-71-stake-in-kokomodo
Pluri shares are trading higher after the ...
01/23/2025 12:17:02

pluri-announces-65m-private-placement-with-investor-alejandro-weinstein-co-will-purchase-71-of-kokomodos-shares
Pluri Announces $6.5M Private Placement Wi...
01/23/2025 12:16:14

pluri-applauds-mesoblast-for-fda-approval-of-first-mesenchymal-stromal-cell-therapy-for-steroid-refractory-acute-graft-versus-host-disease-highlighting-regenerative-medicines-transformative-potential-and-advancing-msc-therapies-in-healthcare
Pluri Applauds Mesoblast For FDA Approval ...
12/19/2024 13:10:06

pluri-assesses-readiness-for-mass-production-of-plx-r18-for-acute-radiation-syndrome
Pluri Assesses Readiness For Mass Producti...
11/25/2024 13:32:04

Core News & Articles
BrainStorm Enters Memorandum Of Understand...
11/11/2024 11:05:38

This MOU enables BrainStorm to begin transfer of its manufacturing technology and start producing NurOwn at Pluri's manufac...

pluri-secures-israel-funding-for-mait-cell-cancer-therapy-teams-up-with-bar-ilan-university-to-target-solid-tumors
Pluri Secures Israel Funding for MAIT Cell...
10/28/2024 11:03:07

Pluri Inc. (NASDAQ:PLUR) (TASE:PLUR) ("Pluri" or the "Company"), a leading biotechnology company that transform...

pluri-partners-with-kadimastem-to-advance-cell-therapy-products-for-clinical-trials
Pluri Partners with Kadimastem to Advance ...
07/18/2024 06:41:36

Leading biotechnology company Pluri Inc. (NASDAQ:PLUR) (TASE:PLUR) ("Pluri" or the "Company"), which transforms...

pluri-announced-1m-proof-of-concept-agreement-to-enhance-global-sustainable-vegetable-supply
Pluri Announced €1M Proof Of Concept Agree...
07/08/2024 11:06:24

 Pluri Inc. (NASDAQ:PLUR) (TASE:PLUR) ("Pluri" or "the Company"), which transforms cells into solutions that pr...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION